Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
2,061,931
-
Share change
-
-376,439
-
Total reported value
-
$878,347
-
Price per share
-
$0.43
-
Number of holders
-
21
-
Value change
-
-$163,815
-
Number of buys
-
5
-
Number of sells
-
8
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q1 2023
As of 31 Mar 2023,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,061,931 shares.
The largest 10 holders included
BVF INC/IL, MORGAN STANLEY, RAYMOND JAMES & ASSOCIATES, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Virtu Financial LLC, Western Wealth Management, LLC, Cambridge Investment Research Advisors, Inc., Raymond James Financial Services Advisors, Inc., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
21
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.